Demographic changes mean that Europe's population is growing increasingly older and in need of more and better care. Eye conditions like cataract are among the most frequently encountered by Europe's elders and healthcare stakeholders have realised that patients must have a choice in accessing the best available treatment options. A conference on 9 July in the European Parliament brought together doctors, Commission representatives and policymakers to raise awareness on the issue. Hosted by MEP Heinz K. Becker (EPP), the conferenced launched policy recommendations on Healthcare and Active Ageing: Patient Choice in Cataract Care and shed light on a growing consensus that patient awareness of and access to ground-breaking cataract treaments must be improved.
Eucomed, the European Medical Technology Industry Association, welcomes the update to class IIa with level of evidence A for device-based remote monitoring in the ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy (CRT). Class IIa therapies are treatments which are found to be useful and effective. The updated class not only reflects research findings which conclude that remote monitoring could help patients at high risk for stroke, but also follows a recent consensus between joint European and American experts on the benefits of remote monitoring for patients with a CRT device.
Today, the leading global medical technology industry associations AdvaMed, COCIR, MITA and MedTech Europe (the alliance of European medical technology industry associations EDMA and Eucomed) applaud the announcement to launch trade negotiations between the United States and European Union.
MedTech Europe, the alliance of European Medical Technology Industry Associations, welcomes new research from the European Health Technology Institute (EHTI) confirming that there is no uniform relationship between medtech innovation and an increase in healthcare expenditure. The impact of medical technology on healthcare costs is a result of multiple, dynamic factors, such as whether a technology expands the number of treatable conditions, improves the capacity of the system to treat more patients, or extends life, inducing additional years of healthcare consumption. Consequently this impact varies greatly and can result in novel technologies being cost-saving, cost-neutral or cost-increasing.
The European cardiovascular medical device industry was presented on 20 May at the annual meeting of the European Association for Percutaneous Cardiovascular Interventions with the Ethica Award for its contribution to improving European patient care. Interventional cardiologists use narrow tubes, or catheters, passed through arteries or veins to reach the heart or other organs to carry out procedures and insert devices to treat disease. The award recognizes the role played by safe, innovative cardiovascular devices in addressing unmet medical needs and improving patient survival rates and quality of life.